Koshika Life science Academy.

An Institute For Biotechnology, LifeSciences & Pharmaceutical Sciences Run By Ex-IITians

Koshika LifeSciences Academy Lucknow is a leading educational firm actively involved in providing guidance in the field of LifeSciences, Biotechnology and Pharmaceutical Sciences. Koshika LifeSciences Academy is established and operated by Ex-IITians. It is a Lucknow based start-up. Founded in July 2008, the institute aims to prepare students for various competitive entrance examinations related to Biotechnology, LifeSciences & Pharmaceutical Sciences by using innovative techniques and methodology. It offers an open platform which can be used by students to increase their knowledge, strengthen fundamentals and finally beat the competitions. Koshika provides correspondence and classroom coaching programmes by well qualified, extrabriliant and experienced faculty members mostly Ex-IITians. Our faculty members are subject experts from different institutes like IIT-Kharagpur, IIT-Roorkee, IT-BHU, JNU/IGIB-Delhi, CDRI, NBRI & SGPGI-Lucknow etc. Koshika offers coaching programme for…

GATE (Biotechnology/LifeSciences) 

CSIR-NET-JRF(LifeSciences)

 

ICMR/DBT-JRF

IIT-JAM

Combined JNU M.Sc (Biotech) Entrance Exam

GPAT (Graduate Pharmacy Aptitude Test)

NIPER-JEE (National Institute of Pharmaceutical science and Research)

Koshika’s formula for success is based on the belief that there is a winner in every student waiting to be discovered. Koshika brings together the most eminent trainers, the most comprehensive study material, and a highly-focused, uniquely intensive training methodology. Koshika’s faculty of teachers, researchers and support staff work throughout the year, analyzing the various Entrance Examinations and structuring future lessons and tests accordingly. Koshika’s Test-Series are therefore extremely rigorous, in tune with the prevailing national standards. They are regarded as the closest simulation of all the exams cited above.

 

Why should a student choose Koshika ?

Highly qualified and experienced teachers, mostly Ex-IITians. from top institutes like IIT Kharagpur, IIT, Roorkee, IT-BHU, CDRI-Lucknow, IGIB-Delhi, SGPGI-Lucknow & many more. Additionally, we organize guest lectures by different subject experts.
Flawless system of administration with strict discipline, not only for students but also for teachers & staff
Excellent results in different entrance exams
Exhaustive, relevant and original study material and Test papers, which are designed to the correct pattern and approved syllabus by our teachers
Learning and competitive environment at Koshika provide the necessary edge & exposure to students.
Integrated approach of teaching, which not only prepares students for written entrance exams but also for different interview exams for M.Tech, M. Pharma & PhD.
Special tutorial classes to discuss doubts of students. This helps a lot in uplifting the knowledge levels of weak & shy students.
Work culture, which creates a hub of entrepreneurs and not just bunch of employees. Everyone owns his/her job and produces best to his/her ability.
Brilliant initiative like online tests, attendance reporting and test score reporting through SMS, email etc.

For more Information on Courses and Training: http://www.koshika.co.in/programme.html

Route Map: Click Here

Contact Details:

Koshika LifeSciences Academy
Address: C-405, 2nd floor, Sahara Plaza, Patrakarpuram, Gomti Nagar, Lucknow-226010 (UP) India
Telephone: 9450190335, 7800369292
E-mail: contact@koshika.co.in

FDA approves first over-the-counter home use HIV test kit

 

The U.S. Food and Drug Administration today approved the OraQuick In-Home HIV Test, the first over-the-counter, self-administered HIV test kit to detect the presence of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2). HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

The OraQuick In-Home HIV Test is designed to allow individuals to collect an oral fluid sample by swabbing the upper and lower gums inside of their mouths, then place that sample into a developer vial, and obtain test results within 20 to 40 minutes. A positive result with this test does not mean that an individual is definitely infected with HIV, but rather that additional testing should be done in a medical setting to confirm the test result.

Similarly, a negative test result does not mean that an individual is definitely not infected with HIV, particularly when exposure may have been within the previous three months. The test has the potential to identify large numbers of previously undiagnosed HIV infections, especially if used by those unlikely to use standard screening methods.

The Centers for Disease Control and Prevention estimates that 1.2 million people in the United States are living with HIV infection. About one in five are not aware they are infected. There are about 50,000 new HIV infections every year. Many of these new infections are transmitted from people who are unaware of their HIV status.

“Knowing your status is an important factor in the effort to prevent the spread of HIV,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The availability of a home-use HIV test kit provides another option for individuals to get tested so that they can seek medical care, if appropriate.”

Clinical studies for self-testing have shown that the OraQuick In-Home HIV Test has an expected performance of 92 percent for test sensitivity, the percentage of results that will be positive when HIV is present. This means that one false negative result would be expected out of every 12 test results in HIV-infected individuals.

Clinical studies also have shown that the OraQuick In-Home HIV Test has an expected performance of 99.98 percent for test specificity, the percentage of results that will be negative when HIV is not present. This means that one false positive would be expected out of every 5,000 test results in uninfected individuals.

OraSure Technologies, the manufacturer of the OraQuick In-Home HIV Test will have a consumer support center that is available via phone and will be open 24 hours a day, seven days a week. The center will be operational and available to educate users with information about HIV/AIDS, the proper method for administering the test and guidance on what to do once results have been obtained once the manufacturer makes the product available for sale to the public. Information about the consumer support center and contact information is included in the test kit.

OraSure Technologies, Inc. is headquartered in Bethlehem, Pa. A version of this test for use by trained technicians in clinical settings was approved in 2004.

Source: FDA

ADMET

9th July - 10th July 2012 | UK

Category: Devices & Diagnostics

Address: The Copthorne Tara Hotel, London, W8 5SR, UK

Organiser: SMi Group

Website: CLICK HERE to open.

**Quote Pharmaphorum and Save £100**

SMi are proud to present their 7th annual ADMET conference, ADMET studies perform a vital role in the drug discovery process. This conference will address the barriers that are currently faced by the PK/PD community and also how recent discoveries have improved the understanding of the mechanisms involved in ADME-Tox. It will also address the new technologies and techniques being developed to overcome the classic physiological barriers to drug bioavailability.

Attendees will hear presentations from senior experts in the field on the current issues as well as case studies from recent drug development programmes.

Reason why you should attend:

• Presentations from a verity of top Pharma companies discussing their approaches to DMPK and Tox studies.

• Half day session focusing on the latest strategies and recommendations for transporter studies and evaluation of potential DDIs

• Case study of the application of drug transporter studies in recent development by Galapagos

• Discussion of the challenges faced by drugs targets to the CNS and how to optimise your drug for CNS penetration.

• Overviews of the latest developments in In-Silico and In-Vitro techniques for predicting the success of new drug candidates

Book your place today!

Alternatively contact Lola Ameh on telephone +44 (0) 20 7827 6722

or email on lameh@smi-online.co.uk

Source:

 

The 2nd Annual Drug Quality and New GMP Summit 2012

10th July - 11th July 2012 | China

Category: Commercial

Address: TBC, Shanghai, China

Organiser: JFPS Group

Website: CLICK HERE to open.

Join us at 2nd Drug Quality and New GMP Summit. Meet with 200 experts from leading pharmaceutical companies.

Comprehensive Theme will be Delivered including:

�?� Difference between new GMP in China and cGMP in Europe

�?� Setting up a risk control system

�?� Risk control tools (FEMA, SWEA, HACCP, etc.) showcase

�?� The application of statistics method in quality analysis

�?� Computer system validation

�?� Change control follow-up

�?� Building up a sustainable facility system

�?� Flexible cold chain

�?� Cleaning validation

�?� Risk management in sterile drug products manufacturing

The 2nd Annual Drug Quality and New GMP Summit will be held on 10-11 July, 2012 in Shanghai, China with plenary meetings and track sessions. The summit is organized by JFPS Group which will gather more than 200 experts from leading pharmaceutical companies to meet and brainstorm on any of the 20 topics covered during the forum. It brings the latest cases on New GMP policies in the industry and will serve as a grand platform for face-to-face communication.

Discover More and Register Now

Event Contact: Grace.Jin

Tel: +86-21-51720125

Email: grace.jin@jfpsgroup.com.cn

Website: http://www.drugqualitysummit.com/

Source:

Vacancy for Drugs Inspector in Drugs Control department of KPSC - Freshers may apply

Gazette Date: 15/06/2012
  Last Date: 19/07/2012
    Category No: 307/2012

Applications must be submitted online through  the official website of the Commission after 'ONE TIME
REGISTRATION' .Candidates who have already registered can apply through their profile.
1 Department : Kerala Drugs Control

2 Name of post : Drugs Inspector
(SR for ST Only)

3 Scale of pay : ` 19,240 -34,500/-

4 No. of vacancies  : 1 (One)

Note:- The  above  Vacancy  is  now  in  existence.  The  Ranked  list  of  selected  candidates  published  by  the
Commission shall remain in force for a minimum period of one year and a maximum period of Three
years provided that the said list will not continue to be in force if a new list after the expiry of the
minimum period of one year is published.  Recruitment will be made for  the above vacancy and also for
the vacancies reported for Special Recruitment (for ST only) during the pendency of the list.

5 Method of Appointment : Direct Recruitment (Special Recruitment from among Scheduled Tribes
only).
Note:- Applications received from candidates other than those Scheduled Tribe candidates will be rejected.
Individual communications regarding the rejection of their applications for the above reason will not be
issued.

6 Age Limit : 21–40.
Only Candidates born between 02.01.1972 and 01.01.1991 (including both
the dates) are eligible to apply for this post. (No other age relaxation will be
allowed)
Note:- In the absence of qualified candidates within the age limit, the upper age limit shall be relaxed up to 50
years. But in no case the maximum age limit shall exceed 50 (Fifty) years.
                                     
7 Qualifications :   1. Degree in Pharmacy of a recognised University.
Note :- Direct recruitees shall shall be on training for six months from the date of joining is
            service
8 Probation : Every person appointed to this post shall be on probation from the date on which he
                  Joins duty for a total period  of two years on duty within a continuous period of three
                  years.
        Note:- Probation of recruitees shall commence after successful completion of training.

9 Test :         Every Person appointed by direct Recruitment shall pass the Account test (Lower) or                  Account Test for Executive Officers during the period of Probation if he has not
                   already passed the same.

10  Mode of submitting applications
Candidates shall register as per 'ONE TIME REGISTRATION ' system on the Official Website of
Kerala  Public Service Commission 'www.keralapsc.org' for applying for the post.  Candidates  who have
registered shall apply by logging in to their  profile using their  User- ID  and password.  Candidates shall click
on the 'Apply Now' button of the respective posts in the Notification link for applying for a post.  No
application fee is required.  Candidates can view and have a print-out of   the details in the profile by clicking
the  link  Registration  Card,  if  required.   Candidates  are  responsible  for  the  correctness  of  the  personal
information and secrecy of password.  Before applying for a post, candidates must ensure correctness of the
information in their  profile.  They must quote the User- ID for further communication with the Commission.
Applications once submitted will be received as provisional and particulars shall not be  deleted or altered after
submission.    Applications submitted not in accordance  with the conditions of the notification will be
summarily rejected. Documents to prove Qualification, experience ,  community, age  etc.  have to be
produced as and when called for . 

11 Last Date for receipt of applications  : 19.07.2012 Thursday up to 12 Midnight.

12 On-line Address to which applications are to be sent :          www.keralapsc.org

13 Paragraphs two, three and twenty five (except the conditions laid down in the Rule 3(C) of Part II of the
Kerala State and Subordinate Services Rules) are not applicable to this selection.

14 Appointments are made subject to the rank secured in the Ranked List of candidates prepared in pursuance of
this notification subject to the conditions laid down in   G.O.(P) No. 21/76/PD dated, 17.01.1976 and G.O.(P)
No. 25/94/GAD dated 22.01.1994 allowing special reservations to Scheduled Tribes in accordance with the
procedures made for this purpose from time to time and subject to the rules under Sections 3 (c), 17 (a), 17(b)
of Part II of Kerala state and subordinate Service Rules, 1958.

15 If a Written Test/OMR Test is conducted as part of the Selection, Hall Ticket of eligible candidates will be
made available in the Website of the Kerala Public Service Commission.
Candidates are instructed to download their Hall Tickets as per the instructions in the Website .
        ( For details including Photo and ID refer to the General Conditions)
P.C.BINOY,
SECRETARY,
KERALA PUBLIC SERVICE COMMISSION

Orginal Notification

Coffee Consumption Inversely Associated With Risk of Most Common Form of Skin Cancer

Increasing the number of cups of caffeinated coffee you drink could lower your risk of developing the most common form of skin cancer, basal cell carcinoma, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
“Our data indicate that the more caffeinated coffee you consume, the lower your risk of developing basal cell carcinoma,” said Jiali Han, Ph.D., associate professor at Brigham and Women’s Hospital, Harvard Medical School in Boston and Harvard School of Public Health.
“I would not recommend increasing your coffee intake based on these data alone,” said Han. “However, our results add basal cell carcinoma to a list of conditions for which risk is decreased with increasing coffee consumption. This list includes conditions with serious negative health consequences such as type 2 diabetes and Parkinson’s disease.”     
Basal cell carcinoma is the form of skin cancer most commonly diagnosed in the United States. Even though it is slow-growing, it causes considerable morbidity and places a burden on health care systems.
“Given the large number of newly diagnosed cases, daily dietary changes having any protective effect may have an impact on public health,” said Han.
Han and his colleagues generated their results by conducting a prospective analysis of data from the Nurses’ Health Study, a large and long-running study to aid in the investigation of factors influencing women’s health, and the Health Professionals Follow-up Study, an analogous study for men.
Of the 112,897 participants included in the analyses, 22,786 developed basal cell carcinoma during the more than 20 years of follow-up in the two studies. An inverse association was observed between all coffee consumption and risk of basal cell carcinoma. Similarly, an inverse association was seen between intake of caffeine from all dietary sources (coffee, tea, cola and chocolate) and risk of basal cell carcinoma. However, consumption of decaffeinated coffee was not associated with a decreased risk of basal cell carcinoma. 
“These results really suggest that it is the caffeine in coffee that is responsible for the decreased risk of basal cell carcinoma associated with increasing coffee consumption,” said Han. “This would be consistent with published mouse data, which indicate caffeine can block skin tumor formation. However, more studies in different population cohorts and additional mechanistic studies will be needed before we can say this definitively.”
In contrast to the findings for basal cell carcinoma, neither coffee consumption nor caffeine intake were inversely associated with the two other forms of skin cancer, squamous cell carcinoma and melanoma, the most deadly form of the disease.
Only 1,953 cases of squamous cell carcinoma and 741 cases of melanoma were recorded among the 112,897 participants included in Han’s analyses.
“It is possible that these numbers are insufficient for any association with coffee consumption to be seen,” said Han. “As the study participants are followed for a longer time, the number of cases of these conditions is likely to increase. We may be in a position in 10 years’ time to better address this issue.”    

Source: AACR

FDA approves new combination vaccine that protects children against two bacterial diseases

 

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

Diseases caused by the bacteria Neisseria meningitidis (meningococcal disease) and Haemophilus influenzae type b (Hib disease) can be life-threatening. These bacteria can infect the bloodstream causing sepsis, and the lining that surrounds the brain and spinal cord causing meningitis. In young children, Neisseria meningitidis andHaemophilus influenzae type b are important causes of bacterial meningitis.

Without vaccination, children younger than two years are susceptible to these serious illnesses. Meningococcal and Hib diseases are particularly dangerous because both diseases often progress rapidly and can cause death or serious, long-lasting health consequences such as blindness, mental retardation, or amputations. Early symptoms for both diseases often are difficult to distinguish from other common childhood illnesses.

“With today’s approval of Menhibrix, there is now a combination vaccine that can be used to prevent potentially life-threatening Hib disease and two types of meningococcal disease in children. It is the first meningococcal vaccine that can be given starting as young as six weeks of age,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

The effectiveness of Menhibrix was based on immune responses in several hundred U.S. infants and toddlers vaccinated with Menhibrix. For the Hib component of the vaccine, immune responses in infants and toddlers following vaccination with Menhibrix were comparable to immune responses in infants and toddlers who received an FDA-approved vaccine against invasive Hib disease.

For the meningococcal component, study results showed that the vaccine produces antibodies in the blood at levels that are considered to be predictive of protection against invasive meningococcal disease caused by serogroups C and Y.

The safety of Menhibrix was evaluated in about 7,500 infants and toddlers in the U.S., Mexico and Australia. Common adverse reactions reported after administration of Menhibrix were pain, redness and swelling at the injection site, irritability and fever.

Menhibrix is given as a four-dose series at 2, 4, 6 and 12 through 15 months of age. The first dose may be given as early as 6 weeks of age. The fourth dose may be given as late as 18 months of age.

Menhibrix is manufactured by GlaxoSmithKline Biologicals, based in Rixensart, Belgium.

Source: FDA

2nd Pharma Supply Chain Forum

27th September - 27th September 2012 | India

Category: Commercial

Address: Taj Lands End, Mumbai, Maharashtra, 400 050, India

Organiser: Kamikaze B2B Media

Website: CLICK HERE to open.

Pharma Supply Chain Forum 2012 is the strategic platform where pharmaceutical, biotech and CROs supply chain and logistics practitioners can meet to discuss challenges in context to Asia

Now in its 2nd year, Pharma Supply Chain Forum is the premier pharmaceutical supply chain and logistics event in India covering a comprehensive range of supply chain topics including (but not limited to): Network optimization, lean management, inventory management, security management, cold chain management, supplier-partner relationship management, packaging technology, forecasting & sourcing, and pedigree compliance.

5 Reasons You And Your Team Must Attend Pharma Supply Chain Forum

* 20+ industry speakers

* In-depth research

* Interactive Think Tank Roundtable discussions

* Tracks covering the latest hot topics

* World Class Networking

To know more about the event log on to www.elscconclave.com/pharma.html or email us atharish@elscconclave.com / bhumika@kamikaze.co.in

Source:

3rd International Conference and Exhibition on Analytical & Bioanalytical Techniques

22nd November - 24th November 2012 | India

Category: Other

Address: Hyderabad International Convention Centre, India

Organiser: OMICS Group Inc.

Website: CLICK HERE to open.

Event Location: Hyderabad International Convention Centre, India

Start Date: November 22, 2012

End Date: November 24, 2012

Link: http://www.omicsonline.org/analyticaacta2012/

Description:

OMICS Group invites you to attend the 3rd International Conference and Exhibition on Analytical & Bioanalytical Techniques during November 22-24, 2012 at Hyderabad International Convention Centre, India. We welcome all the participants from across the world to take part in this premier event.

The Committee is scheduling an exhilarating scientific program that will include plenary and thematic sessions,presentation of research papers and workshops. The program is currently evolving through collaboration between local and international experts and is expected to be very innovative.

Analytica Acta-2012 goal is to provide a scientific platform to meet fellow key decision makers all-around the Pharmaceutical, Biotech, Academic Institutions, Healthcare Institutes making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies related to Analytical and Bioanalytical techniques, making the Congress a perfect platform to share proficiency.

Through the theme - Exploring Scientific Technologies & Industry Insight, the conference aims in promulgating knowledge and facilitating share of new ideas amongst the professionals, industrialists and students from relevant fields.

Source:

Stability Testing Of Pharmaceuticals and Biopharmaceuticals - New Seminar

4th July - 5th July 2012 | UK

Category: Devices & Diagnostics

Address: The Rembrandt Hotel, 11 Thurloe Place, London, 11 Thurloe Place, UK

Organiser: Management Forum Ltd

Website: CLICK HERE to open.

By attending this comprehensive two day seminar delegates will:

• Learn how to design efficient stability studies that are suitable for global marketing

• Be able to carry out appropriate stability studies and manage stability samples and facilities

• Know how to save resource on stability testing and improve the likelihood of regulatory approval of stability protocols.

If you have any questions please click here to email Andrea James

Source: